To compare the treatments used for the first episode of lupus nephritis (LN) in two Latin American cohorts (historical and contemporary) over a 25-year period, and their associations with clinical outcomes.
Methods
Patients with biopsy-confirmed first LN episode were classified as non-proliferative (class V) or proliferative (classes III/IV). Sociodemographic, clinical, and treatment variables were described. Propensity score matching was used to examine the associations with four outcomes: mortality, damage accrual (SDI), hospitalization, and end-stage renal disease (ESRD).
Results
A total of 532 SLE patients were included: 362 from GLADEL 1.0 (historical cohort) and 170 from GLADEL 2.0. (contemporary). Compared to GLADEL 1.0, patients in GLADEL 2.0 received lower doses of oral glucocorticoids (GC), more frequently GC pulses and antimalarials but less frequently cyclophosphamide. An increase in the use of mycophenolate mofetil and other immunosuppressants was also observed. In the logistic regression models, SDI was associated with baseline SDI and GC pulses, whereas belonging to the GLADEL 2.0 was a protective factor. Mortality was associated with Mestizo ethnicity and partial health coverage; antimalarial was identified as a protective factor. Hospitalizations were associated with baseline SLEDAI and SDI, follow-up time, and lower educational level. Belonging to the GLADEL 2.0 cohort was protective against the occurrence of ESRD.
Conclusions
Patients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged. These improvements likely reflect the increased use of newer therapies, more targeted approaches, in line with current treatment guidelines, and better access to specialized care.
FanouriakisATziolosNBertsiasG, et al.Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis2021; 80(1): 14–25. https://doi.org/10.1136/annrheumdis-2020-218272
2.
MahajanAAmelioJGairyK, et al.Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus2020; 29(9): 1011–1020. https://doi.org/10.1177/0961203320932219
3.
TektonidouMGDasguptaAWardMM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol2016; 68(6): 1432–1441. https://doi.org/10.1002/art.39594
4.
ManingdingEDall'EraMTrupinL, et al.Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res2020; 72(5): 622–629. https://doi.org/10.1002/acr.23887
Pons-EstelGJAlarcónGSBurgosPI, et al.Grupo Latino Americano de Estudio de Lupus (GLADEL). Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. Lupus2013; 22(9): 899–907. https://doi.org/10.1177/0961203313496339
7.
Pons-EstelBABonfaESorianoER, et al.First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis2018; 77(11): 1549–1557. https://doi.org/10.1136/annrheumdis-2018-213512
8.
FanouriakisAKostopoulouMCheemaK, et al.Update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis2020; 79(6):713–723. https://doi.org/10.1136/annrheumdis-2020-216924
9.
FanouriakisAKostopoulouMAlunnoA, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78(6): 736–745. https://doi.org/10.1136/annrheumdis-2019-215089
10.
Pons-EstelBACatoggioLJCardielMH, et al.The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among Hispanics. Medicine (Baltim)2004; 83(1): 1–17. https://doi.org/10.1097/01.md.0000104742.42401.e2
11.
TanEMCohenASFriesJF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25(11): 1271–1277. https://doi.org/10.1002/art.1780251101
12.
Gómez-PuertaJAPons-EstelGJQuintanaR, et al.A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: launching the GLADEL 2.0 study group. Lupus2021; 30(4): 630–640. https://doi.org/10.1177/0961203320988586
13.
HochbergMC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40(9): 1725. https://doi.org/10.1002/art.1780400928
14.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686. https://doi.org/10.1002/art.34473
15.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int2018; 93(4): 789–796. https://doi.org/10.1016/j.kint.2017.11.023
16.
GraffarM. A method of social classification of population samples. Courrier VI1956; 6: 455–459.
GladmanDUrowitzMFortinP, et al.Systemic lupus international collaborating clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. J Rheumatol1996; 23(11): 1953–1955.
19.
SeldinMFQiLScherbarthHR, et al.Amerindian ancestry in Argentina is associated with increased risk for systemic lupus erythematosus. Gene Immun2008; 9(4): 389–393. https://doi.org/10.1038/gene.2008.25
20.
SeldinMFTianCShigetaR, et al.Argentine population genetic structure: large variance in Amerindian contribution. Am J Phys Anthropol2007; 132(3): 455–462. https://doi.org/10.1002/ajpa.20534
RobertiJLeslieHHDoubovaSV, et al.Inequalities in health system coverage and quality: a cross-sectional survey of four Latin American countries. Lancet Global Health2024; 12(1): e145–e155. https://doi.org/10.1016/S2214-109X(23)00488-6
23.
SanchezLJohnsonTWilliamsS, et al.Identifying inequities in an urban Latin American population: a cross-sectional study in Australian primary health care. Aust J Prim Health2020; 26(2): 140–146. https://doi.org/10.1071/PY19049
24.
WallaceSPGutiérrezVF. Equity of access to health care for older adults in four major Latin American cities. Rev Panam Salud Públic2005; 17(5-6): 394–409. https://doi.org/10.1590/s1020-49892005000500012
25.
QuintanaRPons-EstelGJRobertsK, et al.Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus2020; 29(9): 1140–1145. https://doi.org/10.1177/0961203320935184
26.
ShinjoSKBonfáEWojdylaD, et al.Antimalarial treatment May have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum2010; 62(3): 855–862. https://doi.org/10.1002/art.27300
27.
Pons-EstelGJCatoggioLJCardielMH, et al.Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus2015; 24(6): 536–545. https://doi.org/10.1177/0961203314567753
28.
FanouriakisAKostopoulouMAndersenJ, et al.EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis2024; 83(1): 15–29. https://doi.org/10.1136/ard-2023-224762
29.
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int2024; 105(1S): S1–S69. https://doi.org/10.1016/j.kint.2023.09.002
30.
Pons-EstelGJQuintanaRUgarte-GilMF, et al.Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients. Lupus2024; 33(13): 1492–1501. https://doi.org/10.1177/0961203324128355
31.
Pons-EstelGJAlarcónGSScofieldL, et al.Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum2010; 39(4): 257–268. https://doi.org/10.1016/j.semarthrit.2008.10.007
32.
Pons-EstelGJSauritVAlarcónGS, et al.The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus2012; 21(13): 1397–1404. https://doi.org/10.1177/0961203312458465
33.
Pimentel-QuirozVRUgarte-GilMFPons-EstelGJ, et al.Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Semin Arthritis Rheum2017; 47(2): 199–203. https://doi.org/10.1016/j.semarthrit.2017.01.012
34.
AlarcónGSRodríguezJLBenavidesGJr, et al.Systemic lupus erythematosus in three ethnic groups. V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA cohort. LUMINA study group. Lupus in minority populations, nature versus nurture. Arthritis Care Res1999; 12(4):267–276.
35.
UribeAGMcGwinGJrReveilleJD, et al.What have we learned from a 10-year experience with the LUMINA (lupus in minorities; nature vs. nurture) cohort? Where are we heading?Autoimmun Rev2004; 3(4): 321–329. https://doi.org/10.1016/j.autrev.2003.11.005
36.
DuránSApteMAlarcónGSLUMINAStudy Group. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc2007; 99(10): 1196–1198.
37.
AlarcónGSBeasleyTMRosemanJM, et al.Ethnic disparities in health and disease: the need to account for ancestral admixture when estimating the genetic contribution to both (LUMINA XXVI). Lupus2005; 14(10): 867–868. https://doi.org/10.1191/0961203305lu2184xx
38.
GasparottoMGattoMBindaV, et al.Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology2020; 59(Suppl5): v39–v51. https://doi.org/10.1093/rheumatology/keaa381
39.
GiscaEDuarteLFarinhaF, et al.Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology2021; 60(4): 1814–1822. https://doi.org/10.1093/rheumatology/keaa491
40.
Bartels-PeculisLSharmaAEdwardsAM, et al.Treatment patterns and health care costs of lupus nephritis in a United States payer population. Open Access Rheumatol2020; 12: 117–124. https://doi.org/10.2147/OARRR.S248750
ParodisILanataCNikolopoulosD, et al.Reframing health disparities in SLE: a critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract Res Clin Rheumatol2023; 37(4): 101894. https://doi.org/10.1016/j.berh.2023.101894
43.
FernándezMAlarcónGSCalvo-AlénJ, et al.A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum2007; 57(4): 576–584. https://doi.org/10.1002/art.22672
WilliamsJNDrenkardCLimSS. The impact of social determinants of health on the presentation, management and outcomes of systemic lupus erythematosus. Rheumatology2023; 62(Suppl 1): i10–i14. https://doi.org/10.1093/rheumatology/keac613
46.
Ugarte-GilMFPons-EstelGJMolinerosJ, et al.Disease features and outcomes in United States lupus patients of Hispanic origin and their mestizo counterparts in Latin America: a commentary. Rheumatology2016; 55(3): 436–440. https://doi.org/10.1093/rheumatology/kev280
47.
Hernández CruzBAlonsoFCalvo AlénJ, et al.Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of hispanics: european Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus2020; 29(1): 27–36. https://doi.org/10.1177/0961203319889667
48.
DimaAJurcutCChassetF, et al.Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis2022; 14: 1759720X211073001. https://doi.org/10.1177/1759720X211073001
49.
CaiTZhaoJYangY, et al.Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies. Lupus2022; 31(14): 1714–1725. https://doi.org/10.1177/09612033221129774
50.
JinZWangFPanW, et al.Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology2021; 60(4): 1774–1783. https://doi.org/10.1093/rheumatology/keaa485
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
